Apogee Therapeutics, Inc.
APGEDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
APG777 | Phase 2 | Atopic Dermatitis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Apogee Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Apogee Therapeutics, Inc.'s (APGE) pipeline across Phase 2. Its lead program is APG777 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Apogee Therapeutics, Inc.'s next FDA catalyst?→
Apogee Therapeutics, Inc.'s (APGE) next tracked catalyst is a Phase 2 expected November 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track APGE biotech catalysts?→
Add APGE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Apogee Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.